Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
ConclusionGiven the overall high cure rates of new DAAs, CHC patients ’ preferences for therapy may be influenced by treatment attributes other than cure rates and tolerability. Treatments that are more convenient and require less disruption to their daily life (e.g., shorter treatment duration, no modification in PPI use, and fewer office visits when on treatment) are important to patients with CHC and should be considered when making treatment decisions.FundingAbbVie.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cholesterol | Drugs & Pharmacology | France Health | Germany Health | Headache | Hepatitis | Hepatitis C | Italy Health | Migraine | Proton Pump Inhibitors PPIs | Spain Health | Statin Therapy | Statistics | Study